This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
July 05, 2017
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
June 28, 2017
Trimb acquires well-established OTC products in Europe
June 27, 2017
Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
June 27, 2017
Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
June 26, 2017
Strongbridge Biopharma plc Added to the Russell 3000® Index
June 21, 2017
Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today
June 20, 2017
Onxeo successfully raises €15 Million with US and European investors
June 19, 2017
Nordic Nanovector to present to investors at the Citi European Healthcare Conference
June 19, 2017
Onxeo launches a capital increase by means of an accelerated book-build offering
June 14, 2017
Tisbury Pharmaceuticals Launches with a USD 32 Million Series A Financing to Develop First-in-class Therapeutics for Glaucoma